National Institute of General Medical Sciences: Notice of Meeting, 75341-75342 [2020-26026]
Download as PDF
<![CDATA[
jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 85, No. 228 / Wednesday, November 25, 2020 / Notices
A2058 (middle) and SK MEL 5
(lower) cell types
—Respondent reused and relabeled the
same source band to falsely
represent two different
experimental results in Figure 5 in
the 2005 AACR Presentation as
follows:
D Figure 5, lane 1 of the seventh row,
in the 2005 AACR Presentation,
representing pBad ser 75 expression
at 0 hour in control group
D Figure 5, lane 2 of the seventh row,
in the 2005 AACR Presentation,
representing pBad ser 75 expression
at 1 hour in control group
Dr. Panka entered into a Voluntary
Settlement Agreement and agreed to the
following:
(1) Respondent agreed to have his
research supervised for a period of three
(3) years beginning on November 9,
2020. Respondent agrees that prior to
the submission of an application for
PHS support for a research project on
which Respondent’s participation is
proposed and prior to Respondent’s
participation in any capacity on PHSsupported research, Respondent shall
ensure that a plan for supervision of
Respondent’s duties is submitted to ORI
for approval. The supervision plan must
be designed to ensure the scientific
integrity of Respondent’s research
contribution. Respondent agrees that he
shall not participate in any PHSsupported research until such a
supervision plan is submitted to and
approved by ORI. Respondent agrees to
maintain responsibility for compliance
with the agreed upon supervision plan.
(2) The requirements for Respondent’s
supervision plan are as follows:
i. A committee of 2–3 senior faculty
members at the institution who are
familiar with Respondent’s field of
research, but not including
Respondent’s supervisor or
collaborators, will provide oversight and
guidance for a period of three (3) years
from the effective date of the
Agreement. The committee will review
primary data from Respondent’s
laboratory on a quarterly basis and
submit a report to ORI at six (6) month
intervals, setting forth the committee
meeting dates and Respondent’s
compliance with appropriate research
standards and confirming the integrity
of Respondent’s research.
ii. The committee will conduct an
advance review of any PHS grant
applications (including supplements,
resubmissions, etc.), manuscripts
reporting PHS-funded research
submitted for publication, and abstracts.
The review will include a discussion
with Respondent of the primary data
represented in those documents and
VerDate Sep<11>2014
16:27 Nov 24, 2020
Jkt 253001
will include a certification to ORI that
the data presented in the proposed
application/publication are supported
by the research record.
(3) Respondent agreed that for a
period of three (3) years beginning on
November 9, 2020, any institution
employing him shall submit, in
conjunction with each application of
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract.
(4) If no supervisory plan is provided
to ORI, Respondent agreed to provide
certification to ORI at the conclusion of
the supervision period that he has not
engaged in, applied for, or had his name
included on any application, proposal,
or other request for PHS funds without
prior notification to ORI.
(5) Respondent agreed to exclude
himself voluntarily from serving in any
advisory capacity to PHS including, but
not limited to, service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant for
a period of three (3) years, beginning on
November 9, 2020.
(6) As a condition of the Agreement,
Respondent will request that the
following papers and conference
abstract be corrected or retracted in
accordance with 42 CFR 93.407(a)(1)
and § 93.411(b):
• Mol Cancer 2011 Sep 19;10:115
• Mol Cancer 2013 Mar 5;12:17
• 2005 AACR Presentation
Respondent will copy ORI and the
Research Integrity Officer at HMS and
BIDMC on the correspondence.
75341
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Neuroscience, Biomarkers and
Therapeutics.
Date: December 7, 2020.
Time: 1:00 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Joseph G. Rudolph, Ph.D.,
Chief and Scientific Review Officer, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5186,
MSC 7844, Bethesda, MD 20892, (301) 408–
9098, josephru@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 19, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–26030 Filed 11–24–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: November 20, 2020.
Elisabeth A. Handley,
Director, Office of Research Integrity, Office
of the Assistant Secretary for Health.
National Institutes of Health
[FR Doc. 2020–26100 Filed 11–24–20; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
General Medical Sciences Council.
The meeting will be open to the
public as indicated below, with a short
public comment period at the end. The
open session will be videocast and can
be accessed from the NIH Videocasting
and Podcasting website (https://
videocast.nih.gov).
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review: Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
National Institute of General Medical
Sciences: Notice of Meeting
E:\FR\FM\25NON1.SGM
25NON1
75342
Federal Register / Vol. 85, No. 228 / Wednesday, November 25, 2020 / Notices
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
jbell on DSKJLSW7X2PROD with NOTICES
Name of Committee: National Advisory
General Medical Sciences Council.
Date: February 3, 2021.
Open: 8:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate for the
discussion of program policies and issues;
opening remarks; report of the Director,
NIGMS; and other business of the Council.
Place: National Institutes of Health,
Natcher Building, Conference Rooms E1 &
E2, 45 Center Drive, Bethesda, MD 20892
(Virtual Meeting).
Closed: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, Conference Rooms E1 &
E2, 45 Center Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Erica L. Brown, Ph.D.,
Acting Associate Director for Extramural
Activities, National Institute of General
Medical Sciences, National Institutes of
Health, Natcher Building, Room 2AN24F,
Bethesda, MD 20892, (301) 594–4499,
erica.brown@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nigms.nih.gov/About/Council, where an
agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859,
Biomedical Research and Research Training,
National Institutes of Health, HHS)
Dated: November 19, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–26026 Filed 11–24–20; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
16:27 Nov 24, 2020
Jkt 253001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health: Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Council of Councils.
The meeting will be held as a virtual
meeting and will be open to the public
as indicated below. Individuals who
plan to view the virtual meeting and
need special assistance or other
reasonable accommodations to view the
meeting, should notify the Contact
Person listed below in advance of the
meeting. The open session will be
videocast and can be accessed from the
NIH Videocasting and Podcasting
website (https://videocast.nih.gov).
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4), and 552b(c)(6), Title 5
U.S.C., as amended. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Council of Councils.
Closed: January 29, 2021.
Time: 10:00 a.m. to 11:00 a.m.
Agenda: Review of Grant Applications.
Place: National Institutes of Health,
Building 1, One Center Drive, Bethesda, MD
20892 (Virtual Meeting).
Open: January 29, 2021.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: Call to Order and Introductions;
Announcements and Updates; NIH Program
Updates; Scientific Talks and Other Business
of the Committee.
Place: National Institutes of Health,
Building 1, One Center Drive, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Franziska Grieder, D.V.M.,
Ph.D., Executive Secretary, Council of
Councils, Director, Office of Research
Infrastructure Programs, Division of Program
Coordination, Planning, and Strategic
Initiatives, Office of the Director, NIH, 6701
Democracy Boulevard, Room 948, Bethesda,
MD 20892, GriederF@mail.nih.gov, 301–435–
0744.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Council of Council’s home page at https://
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
dpcpsi.nih.gov/council/ where an agenda
will be posted before the meeting date.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: November 19, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–26024 Filed 11–24–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute Of Dental &
Craniofacial Research; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Division of Intramural
Research Board of Scientific Counselors,
National Institute of Allergy and
Infectious Diseases.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended for the review, discussion,
and evaluation of individual intramural
programs and projects conducted by the
NATIONAL INSTITUTE OF DENTAL &
CRANIOFACIAL RESEARCH, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, National Institute of Dental and
Craniofacial Research.
Date: December 1–2, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: National Institute of Dental and
Craniofacial Research, National Institutes of
Health, 6701 Democracy Boulevard, Room
660, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Alicia J. Dombroski, Ph.D.,
Director, Division of Extramural Activities,
National Institute of Dental and Craniofacial
Research, National Institutes of Health, 6701
Democracy Boulevard, Room 660, Bethesda,
E:\FR\FM\25NON1.SGM
25NON1
]]>Agencies
[Federal Register Volume 85, Number 228 (Wednesday, November 25, 2020)]
[Notices]
[Pages 75341-75342]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-26026]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of General Medical Sciences: Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Advisory
General Medical Sciences Council.
The meeting will be open to the public as indicated below, with a
short public comment period at the end. The open session will be
videocast and can be accessed from the NIH Videocasting and Podcasting
website (https://videocast.nih.gov).
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and
[[Page 75342]]
the discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: National Advisory General Medical Sciences
Council.
Date: February 3, 2021.
Open: 8:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate for the discussion of program
policies and issues; opening remarks; report of the Director, NIGMS;
and other business of the Council.
Place: National Institutes of Health, Natcher Building,
Conference Rooms E1 & E2, 45 Center Drive, Bethesda, MD 20892
(Virtual Meeting).
Closed: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Natcher Building,
Conference Rooms E1 & E2, 45 Center Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Erica L. Brown, Ph.D., Acting Associate Director
for Extramural Activities, National Institute of General Medical
Sciences, National Institutes of Health, Natcher Building, Room
2AN24F, Bethesda, MD 20892, (301) 594-4499, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: https://www.nigms.nih.gov/About/Council, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.375,
Minority Biomedical Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology, Physiology, and
Biological Chemistry Research; 93.862, Genetics and Developmental
Biology Research; 93.88, Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859, Biomedical Research and
Research Training, National Institutes of Health, HHS)
Dated: November 19, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-26026 Filed 11-24-20; 8:45 am]
BILLING CODE 4140-01-P
